Pharming Group Shares Fall After CEO Resigns Over Strategy Disagreement

Shares of biotechnology company Pharming Group fell sharply on Tuesday following the announcement that Chief Executive Officer Fabrice Chouraqui has stepped down, effective immediately. The company stated the departure follows a strategic disagreement with the board over the execution of its priorities.

Market Reaction

Investors reacted to the leadership uncertainty, with Pharming's stock price dropping by as much as 6.5% during Tuesday's trading session. The shares later recovered some of the losses, trading down 1.63% at €0.905, compared with a closing price of €0.920 on Monday, according to the report.

Sudden executive departures, particularly those attributed to strategic disputes, can create uncertainty for investors regarding a company's future direction and operational stability.

Interim Leadership and Path Forward

Ad

Pharming Group, which develops treatments for rare diseases, has appointed two executives to lead the company on an interim basis. The new co-CEOs are:

• Chief Commercial Officer Leverne Marsh, who will oversee patient-focused operations.
• Chief Financial Officer Kenneth Lynard, who will be responsible for global corporate functions.

The company confirmed that its board has begun the search for a permanent chief executive. Despite the management change, Pharming stated that its corporate strategy and development pipeline remain unchanged.